Trial Profile
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Cetuximab; Docetaxel; Everolimus; Paclitaxel; Pembrolizumab
- Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Gastric cancer; Oesophageal cancer; Renal cell carcinoma; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pharmacyclics
- 03 Nov 2023 Results published in the BMC Cancer.
- 17 Sep 2021 Status changed from active, no longer recruiting to completed.
- 30 Dec 2020 Planned End Date changed from 1 Apr 2022 to 30 Nov 2021.